Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iAnthus Capital HoldingsFRA:2IA EV-to-EBIT is -17.30 as of Aug. 01, 2026. The stock has 4 warning signs investors should review. Among 692 Drug Manufacturers companies, iAnthus Capital Holdings ranks worse than 144508.53% on this metric.
iAnthus Capital Holdings (FRA:2IA) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
iAnthus Capital Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was €194.7 Mil.
iAnthus Capital Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iAnthus Capital Holdings EV-to-EBIT Related Terms
iAnthus Capital Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, iAnthus Capital Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iAnthus Capital Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iAnthus Capital Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where iAnthus Capital Holdings's EV-to-EBIT falls into.
iAnthus Capital Holdings's current Enterprise Value is €213.4 Mil.
iAnthus Capital Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iAnthus Capital Holdings (FRA:2IA) has a EV-to-EBIT of -17.30 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on iAnthus Capital Holdings and its competitors. According to the industry distribution chart, iAnthus Capital Holdings ranks #999999 out of 692 companies in the Drug Manufacturers industry.
Is iAnthus Capital Holdings' EV-to-EBIT too high?
iAnthus Capital Holdings' current EV-to-EBIT is -17.30. Based on the distribution chart, iAnthus Capital Holdings ranks #999999 out of 692 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does iAnthus Capital Holdings' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, iAnthus Capital Holdings ranks #999999 out of 692 companies for EV-to-EBIT. This places iAnthus Capital Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on iAnthus Capital Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iAnthus Capital Holdings's current EV-to-EBIT is -17.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iAnthus Capital Holdings stock overvalued right now?
iAnthus Capital Holdings (FRA:2IA) has a current EV-to-EBIT of -17.30. The current EV-to-EBIT is -17.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For iAnthus Capital Holdings (FRA:2IA), the current EV-to-EBIT is -17.30 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
iAnthus Capital Holdings Inc is a vertically-integrated, multi-state owner and operator of licensed cannabis cultivation, processing, and dispensary facilities and a developer, producer, and distributor of branded cannabis products in the United States. Its Cannabis product offerings include flower and trim, products containing cannabis flower and trim (such as packaged flower and pre-rolls), cannabis infused products (such as topical creams and edibles), and products containing cannabis extracts (such as vape cartridges, concentrates, live resins, wax products, oils, and tinctures). The company's reportable operating segments are the Eastern Region, which generates the maximum revenue, and the Western Region.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2IA has been successfully added to your 
